Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mutagenesis of mouse myeloma cells with 'Melphalan'.

× No keyword cloud information.

12 in total

1. Primary structure of a variable region of the V kappa I subgroup (ISE) in light chain deposition disease.

Authors: A Rocca; A A Khamlichi; P Aucouturier; L H Noël; L Denoroy; J L Preud'homme; M Cogné
Journal: Clin Exp Immunol Date: 1993-03 Impact factor: 4.330

2. Time-dependent resistance or susceptibility of tumor cells to cytotoxic antibody after exposure to a chemotherapeutic agent.

Authors: P J Leibson; H Schreiber; M R Loken; S Panem; D A Rowley
Journal: Proc Natl Acad Sci U S A Date: 1978-12 Impact factor: 11.205

3. Antigen-binding mutants of mouse myeloma cells.

Authors: W D Cook; M D Scharff
Journal: Proc Natl Acad Sci U S A Date: 1977-12 Impact factor: 11.205

4. Variants of mouse myeloma cells that produce short immunoglobulin heavy chains.

Authors: B K Birshtein; J L Preud'homme; M D Scharff
Journal: Proc Natl Acad Sci U S A Date: 1974-09 Impact factor: 11.205

5. Cell-free translation of immunoglobulin messenger RNA from MOPC-315 plasmacytoma and MOPC-315 NR, a variant synthesizing only light chain.

Authors: M Green; P N Graves; T Zehavi-Willner; J McInnes; S Pestka
Journal: Proc Natl Acad Sci U S A Date: 1975-01 Impact factor: 11.205

Mutagenesis of mouse myeloma cells with 'Melphalan'.

1. Primary structure of a variable region of the V kappa I subgroup (ISE) in light chain deposition disease.

2. Time-dependent resistance or susceptibility of tumor cells to cytotoxic antibody after exposure to a chemotherapeutic agent.

3. Antigen-binding mutants of mouse myeloma cells.

4. Variants of mouse myeloma cells that produce short immunoglobulin heavy chains.

5. Cell-free translation of immunoglobulin messenger RNA from MOPC-315 plasmacytoma and MOPC-315 NR, a variant synthesizing only light chain.

6. Heavy chain loss after treatment with Melphalan in a patient with "nonsecretory" myeloma.

7. Intracytoplasmic and surface-bound immunoglobulins in "nonsecretory" and Bence-Jones myeloma.

8. Variants of a mouse myeloma cell line that synthesize immunoglobulin heavy chains having an altered serotype.

9. Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.

Review 10. Tumor progression in metastasis: an experimental approach using lectin resistant tumor variants.